Conditions: Parkinson's Disease
Keywords: Parkinson's Rasagiline Mesylate
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 1174
Healthy volunteers: no

Brief summary:
A 2 phase study to evaluate disease progression in Parkinson's disease patients taking rasagiline

Detailed description:

Arms:
arm 1: 1mg early start active treatment arm (72 weeks active)followed by 1mg 36 week delayed start active treatment arm (36 weeks placebo followed by 36 weeks active) arm 2: 2mg early start active treatment arm (72 weeks active)followed by 2mg 36 week delayed start active treatment arm (36 weeks placebo followed by 36 weeks active) arm 3: Each arm is followed by 36 weeks of placebo

Interventions: intervention 1: Rasagiline Mesylate intervention 2: Rasagiline Mesylate intervention 3: Placebo
Intervention descriptions: intervention 1: tablet, 1mg once daily intervention 2: tablet, 2mg once daily intervention 3: Placebo

Protocol document: